Red
Brand Name(s):Lucentis
Indication:Neovascular (wet) age-related macular degeneration and macular oedema secondary to retinal vein occlusion
Rationale:1,2,8
Considered:Oct-06
Review Date:Jan-22
Comments:
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
– details can be found at:tp://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf
Nov 2013